24Sep

New AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC

As demand for rapid testing continues to accelerate at an unprecedented level, our response to assisting testing on a global scale must be in place to support accurate, reliable and easy-to-use testing. 

The AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC, achieves 98.03% sensitivity and 99.5% specifically, will play an invaluable role in overcoming unpredicted rapid testing outcomes.


Download the whitepaper to learn:

  • How the body responds to SARS-COV-2
  • The different approaches to antibody testing
  • The UK-RTC Abc-19 Rapid Test
  • The link between antibodies and immunity
  • The route towards therapies and immunisation 

Please access the complete whitepaper for this device here.

Related

Proteome Sciences plc announce Good Clinical Laboratory Practice Accreditation

Proteome Sciences are pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) ac...

Read More >

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, ...

Read More >

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most esta...

Read More >

Cytox raises £2.6m led by Catapult Ventures to launch predictive testing service for Alzheimer’s disease

Investment will help commercialize Cytox’s services for testing for Alzheimer’s disease and grow C...

Read More >

Hands-on lateral flow test development workshop

BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar...

Read More >